Interactions between two human iodothyronine-binding autoantisera and three preparations of human thyroglobulin (Tg) were not proportional to the latter's thyroxyl residue content. Probably only one of the several thyroxyl-containing sites in Tg reacted with the immunoglobulins from both antisera. In the case of one of the antisera, which was thyroxine (T4)-specific, the thyroxyl residue was the immunodominant feature of the antigenic site. The other antiserum, which had a specificity for 3,5,3'-triiodothyronine (T3), recognized different determinants around the same thyroxyl residue, but this residue was not itself an important element of the binding site. Thus, despite the specificity for T3 free in solution, the presence of T4 in the complete antigenic site was tolerated, since other structures supplied the bulk of the binding energy. 'Specificity' of this antiserum for T3 in solution is therefore coincidental and need not be ascribed to the presence of T3 in the original immunogen. Some results obtained in these studies may be interpreted as supporting the possibility that a modified Tg was the immunogen for the generation of these naturally occurring human antisera.
Interactions between two human iodothyronine-binding autoantisera and three preparations of human thyroglobulin (Tg) were not proportional to the latter's thyroxyl residue content. Probably only one of the several thyroxyl-containing sites in Tg reacted with the immunoglobulins from both antisera. In the case of one of the antisera, which was thyroxine (T4)-specific, the thyroxyl residue was the immunodominant feature of the antigenic site. The other antiserum, which had a specificity for 3,5,3'-triiodothyronine (T3), recognized different determinants around the same thyroxyl residue, but this residue was not itself an important element of the binding site. Thus, despite the specificity for T3 free in solution, the presence of T4 in the complete antigenic site was tolerated, since other structures supplied the bulk of the binding energy. 'Specificity' of this antiserum for T3 in solution is therefore coincidental and need not be ascribed to the presence of T3 in the original immunogen. Some results obtained in these studies may be interpreted as supporting the possibility that a modified Tg was the immunogen for the generation of these naturally occurring human antisera.
Thyroglobulin (Tg) is a heterogeneous glycoprotein (mol.wt. 660000) which is synthesized within the thyroid gland. Some of its tyrosine residues are subsequently iodinated and pairs of these iodotyrosines are enzymically coupled to form the iodothyronines (80-95% T4, 5-15% T3, and the balance rT3), which remain covalently linked within the peptide backbone of the protein. This iodinated Tg is stored within the thyroid follicles. The protein is always heterogeneous with respect to its iodothyronine content, both in type and number, owing to variations in iodine supply and the rate of secretion of thyroid hormone, but may contain up to eight such residues (Marriq et al.,1980) . The process of thyroid-hormone secretion involves endocytosis and enzymic breakdown of Tg with liberation of T4, T3 and rT3. During this process some Tg is released into the blood. Thyroglobulin is thus a normal constituent of blood, certainly from the time of birth and probably earlier, but despite this, autoantibodies to Tg commonly develop, often in association with thyroid disease. It is not known if native Tg is the immunogen giving rise to the antibodies in this situation as a consequence of some fault in immune Abbreviations used: Tg, thyroglobulin; T4, thyroxine (3, 5, 3',  T3, 3,5,3'-tri-iodo- thyronine; rT3, reverse T3 (3,3 ',5'-tri-iodothyronine); surveillance, or whether the structure of Tg has been modified in some way so as to render it immunogenic. Some human autoantibodies to Tg are directed against sequences in the molecule which include T4 and these also bind T4 free in solution (Pearce et al., 1981) . Autoantibodies interacting specifically with T3 have also been described. It is assumed that these latter are also generated against thyroglobulin, but it is not known whether the original immunogenic site contained tri-iodothyronine as a result of incomplete iodination of tyrosine residues or if an 'imperfect' autoantibody was produced against a T4-containing sequence.
This study was undertaken firstly to establish whether all of the thyroxyl residues within Tg can interact with antibodies and, if not, to identify differences between thyroxyl-containing sites, and secondly, to confirm that T3-specific autoantibodies are produced against thyroglobulin and to explain how they may be generated by a predominantly T4-containing immunogen. To these ends we have examined the antigenic properties of iodothyronine residues within native Tg and enzymically produced fragments of Tg with the aid of three different antisera: two spontaneous human antisera which interact with iodothyronines and one ovine antiserum to T4. One of the human antisera bound T4 and the other T3. The sheep antiserum had been 0306-3275/82/120471-08$01.50/1 (© 1982 The Biochemical Society raised by immunization with a T4-bovine serum albumin conjugate.
Materials and methods

Antisera
(1) hT4Ab. This was a human serum from a hypothyroid patient containing autoantibodies to thyroglobulin; 70% of these antibodies reacted with T4-containing sites in the protein and also had a strong specificity for T4 free in solution. Full characterization of this antiserum has been reported (Pearce et al., 1981) . By using [12511IT4 as tracer, the cross-reactivities with the antiserum were (that for T4 being arbitrarily defined as 1.0); T3, 0.01; rT3, 0.004; and Tg, 1.0-2.2, depending on the preparation.
(2) hT3Ab. This was a human serum found by chance in a euthyroid individual containing antibodies which had a high specificity for T3 free in solution. This serum has not been described previously. By using [1251IT3 as tracer, cross-reactivities with the antiserum were (T3 = 1.0): T4, 0.05; rT3, 0.0005; and Tg, 0.3-0.8, depending on the preparation.
(3) sT4Ab. This was a commercial product from Advanced Laboratory Techniques (Tunbridge Wells, Kent, U.K.) raised in sheep against a T4-bovine serum albumin conjugate. It was shown previously (Pearce et al., 1981) to cross-react with human thyroglobulin through thyroxyl residues.
All three antisera were stripped of endogenous iodothyronines before use by multiple (>8) passes through a column of Amberlite CG 400 ion-exchange resin (1 ml/ml of serum (Ornstein, 1965; Davis, 1965) , each Tg preparation showed two closely spaced bands staining approximately equally with Amido Schwarz, with no evidence for faster-or slower-running components.
Iodothyronine contents of thyroglobulins were determined by conventional radioimmunoassays of total enzymic digests of the proteins.
Enzymic degradation ofhuman thyroglobulin DCC-trypsin was obtained from Seravac Laboratories, Maidenhead, Berks., U.K.; chymotrypsin, Pronase P and aminopeptidase M were from Sigma (London) Chemical Co., Poole, Dorset, U.K.
All steps were carried out in glass containers to avoid the irreversible losses that occur on plastic surfaces. Tg (4-20mg/ml) was reduced in 8 M-urea by using 2.43,p1 of mercaptoacetic acid/mg of Tg at pH 10.5 for 90min at room temperature, as recommended by Pitt-Rivers (1976 incubation at 370 C. After 24h incubation two peaks of immunoreactivity were detected by a T4 radioimmunoassay: one close to the void volume of the column the other at a volume corresponding to a mol.wt. of about 1500. With further digestion all the immunoreactivity was found in the lowermolecular-weight region. Analysis of the digest after chymotrypsin-plus-Pronase P treatment by ionexchange chromatography in a conventional amino acid analyser (Beckman 121MB) revealed a few amino acids and many short peptides. The subsequent aminopeptidase treatment degraded the material to free iodothyronines and amino acids. Immunoreactive peptides were not isolated at any stage of digestion in order to avoid the losses that would have prevented a quantitative assessment of changes in cross-reactivity as Tg was fragmented. It was also not necessary, since study could be restricted to T4-containing fragments by using '25I-labelled iodothyronine tracers and the specificity of the antisera.
Antibody-binding studies
Pure iodothyronines for standards were purchased from Henning, Berlin, Germany. High-specificradioactivity (> 1200,Ci/pg) [ (Lowry et al., 1951 ) assuming a mol.wt. of 660000. Values for the products of enzymic digestion of the protein were calculated from the molar quantity of Tg from which they were derived, without correction for the presence of the subunits.
Interactions of substances with the antisera were assessed both in terms of cross-reactivity, defined as the ratio of the molar quantities of two substances required to achieve a given degree of inhibition of tracer binding to antibodies (usually 50% of the maximum), and also in some cases the shape of the dose-response curve of tracer binding in the presence of increasing quantities of test substance.
Results
Interactions with the thyroxine-specific antisera hT4Ab and sT4Ab
Human thyroglobulin preparations TgR and TgE from euthyroid tissue contained similar amounts of iodothyronine residues per mol but more than did TgC extracted from thyrotoxic tissue ( Table 1 ). All three Tg preparations inhibited the binding of [125I1T4 tracer to the antisera hT4Ab and sT4Ab in a dose-dependent fashion (Fig. 1) . The doseresponse curves were parallel with those for T4, and full inhibition of binding could be achieved, confirming our previous observations (Pearce et al., 1981) . However the cross-reactivities of TgR, TgE and TgC versus T4 with both antisera bear no relationship to either the thyroxyl or total iodothyronine contents of the proteins (Table 1 and Fig. 1 ). Individual iodothyronine residues within Tg must therefore vary in their accessibility and reactivity with the immunoglobulins of these sera. Despite TgR and TgE containing 4.2 and 4.0 thyroxyl residues respectively per mol, they had cross-reactivities with hT4Ab close to that of T4 (i.e. 1.1 and 1.0) (see Table 1 and Figs. lc and le) . On the other hand, TgC, with only 1.1 residues of thyroxine per mol, cross-reacted 1.5 times better than did T4 (Table 1 and Fig. la) . It is therefore likely that preparations TgR and TgE contain thyroxyl residues not available to bind with hT4Ab and, in view of the high reactivity of TgC, only one iodothyronine-containing site may be capable of interaction with this antiserum. Steric hindrance to the approach of a second immunoglobulin after the first has bound is possible and will be discussed below.
The dose-response curves for the inhibition of tracer binding by enzymic digests are plotted according to the molar quantities of Tg from Inhibition of '25I-labelled thyroxine tracer binding to the human anti-T4 autoantibody, hT4Ab (a,c,e) and to the sheep anti-T4 antibody, sT4Ab, (b,d,f) by the three thyroglobulins (W), their tryptic digests (A), their total digests (0) and thyroxine (0). Molar quantities of the enzyme digests were determined from the quantities of thyroglobulin from which they were derived.
which they were derived without correction for the presence of subunits or for thyroxyl or total iodothyronine content. Enzymic degradation generally increased the cross-reactivity of each Tg preparation, resulting in dose-response curves displaced to the left of the respective Tg curve (Table 2 and Fig. 1 ).
In most cases the reactivity increased in the order Tg < tryptic digest < total enzymic digest, presumably because increasing degradation of the molecule increased accessibility of thyroxyl residues. The exception was the lesser interaction of the tryptic digest of TgC with the human autoantibody hT4Ab than that of intact TgC (Table 2 and Fig. la) ; the reactivity of the total digest of TgC, however, was greater than either of these.
Increased reactivities in the digests reflect either the exposure of thyroxyls previously buried within the protein, or the removal of steric constraints that had prevented immunoglobulins from simultaneously binding to all exposed T4 residues. A third variable is evident in the results from preparation TgC. It contained a mean of 1.1 mol of T4 residues/ mol and thus would have generated only 1.1 mol of T4-containing fragments after tryptic digestion. Fig. 1(d) Fig. 2(b Cross-reactivities of all three Tg preparations versus T4 for binding to the sheep antiserum were lower than with the human antiserum ( Table 1) . The dose-response curves were set to the right of that for T4 and parallel with it (Figs. lb, Id and iJ) . This is not unexpected, since the sheep antiserum was raised against T4 linked to an albumin side chain rather than within the peptide backbone as in Tg, and it would thus recognize only the thyroxyl moiety. This supports the inferences above that structural features in Tg other than the T4 moiety are involved in binding to hT4Ab.
As before, the cross-reactivities of the three Tg preparations with sT4Ab are not proportional to either their thyroxyl or total iodothyronine contents. Both TgC and TgE, with thyroxyl residue contents of 1.1 and 4.0 respectively per mol, had the same cross-reactivity (0.4) versus T4 (Table 1 and Figs. lb and IJ) in binding to sT4Ab. TgE therefore contains thyroxyl residues which are inaccessible to the sheep immunoglobulins and, as was inferred for the human serum, probably only one thyroxyl was involved in the interactions, since TgC has only one. This must be the same one that reacts with the human serum hT4Ab. However, TgR is 1.8 times as effective as TgE at inhibiting (125I1T4 binding to sT4Ab (Tables 1 and 2 and Figs. ld and if), although both contain similar average numbers of thyroxyl residues per mol (4.2 and 4.0 respectively). This can only be explained in terms of differences in reactivity between the thyroxyl residues, although the precise reason is not clear. Most probably TgR contains an additional thyroxyl accessible to the sheep but not to the human antibodies, so that steric hindrance to the approach of more than one immunoglobulin does not explain all the differences in reactivity. It would seem, therefore, that thyroxyl synthesis in vivo is possible at more than four sites. Each of the three thyroglobulin preparations studied here contains a thyroxyl at the site with which human serum hT4Ab interacts. But the additional thyroxyl residues in TgR and TgE would seem to be differently distributed among more than three sites. that requires conformational determinants and/or neighbouring amino acids present only in the native thyroglobulin for full reactivity. The thyroxyl which reacts with the human antibody probably reacts with the sheep antibody, but TgR seems also to contain another thyroxyl that interacts only with sT4Ab.
Interactions with T3-specific human serum hT3Ab
Only TgR, TgC and their degradation products were tested against this antiserum. Both Tg preparations inhibited the binding of [1251I]T3 tracer to the antiserum in a dose-dependent fashion, and full inhibition could be obtained (Fig. 2) , thus indicating that the antibodies were indeed raised against human Tg.
Both thyroglobulin preparations cross-reacted with T3 better than would be expected from their low T3 contents (Table 1 and Fig. 2) , and once again TgC was the more potent of the two, showing that reactivity with this antiserum is also not related to the iodothyronine content of thyroglobulin. Since the 4.2 mol of thyroxyl residues of TgR do not confer more reactivity than the 1.1 mol of such residues in TgC, it is likely that the hT3Ab reacts with one site only in Tg. If both hT3Ab and hT4Ab react with one site only, and that is the one present in TgC, then it must be concluded that they interact with the same epitope. Both Tg preparations were much more reactive than was T4 (Table 2 and Fig. 2 ).
Changes in cross-reactivity on enzymic degradation of the two thyroglobulins were more complex than those seen with the T4-specific human autoantibody hT4Ab (Fig. 2) . The tryptic digest from TgR was more reactive than the native protein, as indicated by the shift to the left in the dose-response curve, presumably due to exposure of more thyroxyl sites (Table 2 and Fig. 2b ). But when this digest was further degraded to amino acids and iodothyronines, the reactivity declined substantially to equal that of native TgR. Clearly the thyroxyls are much more reactive with this antiserum when they are within their peptide sequence, as confirmed by the poor cross-reactivity of T4 ( Fig. 2 
Discussion
Direct analytical methods applied to Tg preparations from several species have shown that, in general, the first tyrosine residues to be iodinated are also the first to couple into iodothyronines (Lamas et al., 1974; Deme et al., 1976; Gavaret et al., 1977; Vignal et al., 1978) and that the different thyroxyls in Tg are synthesized in an order that is controlled by the tertiary structure of the protein (Rolland et al., 1972; Lamas et al., 1974; Deme et al., 1976; Gavaret et al., 1977; Maurizis et al., 1981) . It is implicit in these observations that the iodothyronine-synthesizing sites in Tg differ in some way. Our studies on the antigenicity of these sites agree with this conclusion. Preparation TgC was the most reactive with both human antisera, although it contained only a mean of 1.1 mol of T4 residues per mol, which must largely represent the first T4 residue to be synthesized. Ochi et al. (1972) , who showed in rabbits that denatured human Tg produced iodothyronine-binding antibodies, but that native Tg did not. It remains possible, however, that the antigenic site straddles two adjacent peptide chains which are parted by tryptic digestion and that the loss of a determinant is responsible for the effects.
Conclusions
The present study of the interactions of human thyroglobulin with two human autoantibodies and one ovine antiserum to a T4-albumin conjugate has thrown light on the antigenic properties of thyroxylcontaining sites in Tg. (i) It has confirmed that a T3-specific antiserum was raised against human Tg and given an explanation for its production by a presumed T4-containing immunogen. (ii) The extent of the interaction between each thyroglobulin and each antiserum was unrelated to the number of iodothyronine residues within each thyroglobulin molecule. Indeed, as far as the two human antisera were concerned, TgC, with the least iodothyronine content, was the most effective preparation at inhibiting [l25Iliodothyronine tracer binding to antibodies. (iii) The human T4-specific antiserum could react with only one of the possible T4-containing sites in Tg; the thyroxyl moiety was an immunodominant feature of the antigenic site and the interaction also involved adjacent structures in native Tg. (iv) It was inferred that the human T3-specific antiserum also reacted with this same site, albeit with a different specificity; there was a high degree of interaction with neighbouring amino acids and the iodothyronine was only a minor determinant.
The presence of T4 in the antigenic site in Tg could therefore be tolerated and the production of a coincidentally T3-specific immunoglobulin was an adequate immune response. (v) The antigenic site for these two antisera is around the first iodothyronine residue synthesized in Tg.
